FDA Panel Votes Against First-line Use For Luitpold’s Iron Deficiency Drug Injectafer
This article was originally published in The Pink Sheet Daily
Executive Summary
Concerned about off-label use of the drug in patients with critical kidney disease, advisory committee suggests that if approved, Injectafer label should include “very descriptive prescribing” instructions.
You may also be interested in...
Daiichi/Luitpold’s Iron Deficiency Anemia Product Injectafer “Not Approvable”
FDA requires additional studies to resolve safety issues, Luitpold says.
Daiichi/Luitpold’s Iron Deficiency Anemia Product Injectafer “Not Approvable”
FDA requires additional studies to resolve safety issues, Luitpold says.
Investors Iron Out AMAG Ferumoxytol Doubts
Shades of MGI’s Aloxi: CMS rule could pay off.